Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, cookie and device IDs
as described in our Privacy Policy.